Revolution Medicines, Inc. (RVMD) Tops Q4 EPS by 19c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q4 EPS of ($0.63), $0.19 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $15.33 million versus the consensus estimate of $7.8 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c